# Hansoh BioMedical R&D Company: Phase 2 study started recruiting, 76 planned (Non-Small Cell Lung Cancer)

**Score:** 95/100

| Field | Value |
|---|---|
| Sponsor | Hansoh BioMedical R&D Company |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations |
| NCT ID | NCT07824882 |
| Phase | Phase 2 |
| Status | recruiting |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention types | drug |
| Target enrollment | 76 |
| Site countries | China |
| Posted | 2026-09-17 |
| Planned start | 2026-10-08 |
| Event | Started recruiting |
| Event date | 2026-10-08 |
| Last update posted | 2026-10-23 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Just started recruiting: sites, recruitment and supply are active.
- Phase 2: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07824882). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.